Literature DB >> 25462192

DAMPs and neurodegeneration.

John Thundyil1, Kah-Leong Lim2.   

Abstract

The concept of neuroinflammation has come a full circle; from being initially regarded as a controversial viewpoint to its present day acceptance as an integral component of neurodegenerative processes. A closer look at the etiopathogenesis of many neurodegenerative conditions will reveal a patho-symbiotic relationship between neuroinflammation and neurodegeneration, where the two liaise with each other to form a self-sustaining vicious cycle that facilitates neuronal demise. Here, we focus on damage associated molecular patterns or DAMPs as a potentially important nexus in the context of this lethal neuroinflammation-neurodegeneration alliance. Since their nomenclature as "DAMPs" about a decade ago, these endogenous moieties have consistently been reported as novel players in sterile (non-infective) inflammation. However, their roles in inflammatory responses in the central nervous system (CNS), especially during chronic neurodegenerative disorders are still being actively researched. The aim of this review is to first provide a general overview of the neuroimmune response in the CNS within the purview of DAMPs, its receptors and downstream signaling. This is then followed by discussions on some of the DAMP-mediated neuroinflammatory responses involved in chronic neurodegenerative diseases. Along the way, we also highlighted some important gaps in our existing knowledge regarding the role of DAMPs in neurodegeneration, the clarification of which we believe would aid in the prospects of developing treatment or screening strategies directed at these molecules.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DAMPs; Inflammasomes; Neurodegeneration; Neuroinflammation; PRRs

Mesh:

Substances:

Year:  2014        PMID: 25462192     DOI: 10.1016/j.arr.2014.11.003

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  25 in total

1.  Sub-region-Specific Optic Nerve Head Glial Activation in Glaucoma.

Authors:  Kazuya Oikawa; James N Ver Hoeve; Leandro B C Teixeira; Kevin C Snyder; Julie A Kiland; N Matthew Ellinwood; Gillian J McLellan
Journal:  Mol Neurobiol       Date:  2020-04-07       Impact factor: 5.590

2.  Administration of 17β-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice.

Authors:  Marius Heitzer; Sarah Kaiser; Mithila Kanagaratnam; Adib Zendedel; Philipp Hartmann; Cordian Beyer; Sonja Johann
Journal:  Mol Neurobiol       Date:  2016-12-12       Impact factor: 5.590

3.  Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms.

Authors:  Hannah Aucott; Johan Lundberg; Henna Salo; Lena Klevenvall; Peter Damberg; Lars Ottosson; Ulf Andersson; Staffan Holmin; Helena Erlandsson Harris
Journal:  J Innate Immun       Date:  2018-02-23       Impact factor: 7.349

4.  Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.

Authors:  Andrew J Kwilasz; Suzanne M Green Fulgham; Julissa Chante Duran-Malle; Anouk E W Schrama; Eric H Mitten; Laurel S Todd; Hardik P Patel; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Lewis O Harvey; Steven F Maier; Raymond A Chavez; Kenner C Rice; Anne-Marie Van Dam; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2021-01-07       Impact factor: 7.217

5.  The Enemy within: Innate Surveillance-Mediated Cell Death, the Common Mechanism of Neurodegenerative Disease.

Authors:  Robert I Richards; Sarah A Robertson; Louise V O'Keefe; Dani Fornarino; Andrew Scott; Michael Lardelli; Bernhard T Baune
Journal:  Front Neurosci       Date:  2016-05-10       Impact factor: 4.677

Review 6.  Sterile Neuroinflammation and Strategies for Therapeutic Intervention.

Authors:  Manoj Banjara; Chaitali Ghosh
Journal:  Int J Inflam       Date:  2017-01-03

Review 7.  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Authors:  Andrea Terron; Anna Bal-Price; Alicia Paini; Florianne Monnet-Tschudi; Susanne Hougaard Bennekou; Marcel Leist; Stefan Schildknecht
Journal:  Arch Toxicol       Date:  2017-12-05       Impact factor: 5.153

8.  The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes.

Authors:  Alessia Serrano; Claudia Donno; Stefano Giannetti; Mina Perić; Pavle Andjus; Nadia D'Ambrosi; Fabrizio Michetti
Journal:  Mediators Inflamm       Date:  2017-06-20       Impact factor: 4.711

Review 9.  Neuroinflammatory paradigms in lysosomal storage diseases.

Authors:  Megan E Bosch; Tammy Kielian
Journal:  Front Neurosci       Date:  2015-10-30       Impact factor: 4.677

Review 10.  Targeting Neuroinflammation to Treat Alzheimer's Disease.

Authors:  A Ardura-Fabregat; E W G M Boddeke; A Boza-Serrano; S Brioschi; S Castro-Gomez; K Ceyzériat; C Dansokho; T Dierkes; G Gelders; Michael T Heneka; L Hoeijmakers; A Hoffmann; L Iaccarino; S Jahnert; K Kuhbandner; G Landreth; N Lonnemann; P A Löschmann; R M McManus; A Paulus; K Reemst; J M Sanchez-Caro; A Tiberi; A Van der Perren; A Vautheny; C Venegas; A Webers; P Weydt; T S Wijasa; X Xiang; Y Yang
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.